Cas 200698-31-3,2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid

200698-31-3

Post Buying Request

Basic information

Product Name: 2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid
Synonyms: 2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid
CAS NO:200698-31-3
Molecular Formula:
Molecular Weight: 508.551
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid(CAS DataBase Reference)
NIST Chemistry Reference: 2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid(200698-31-3)
EPA Substance Registry System: 2,4-Di(benzyloxycarbonyl)butyl(3-phenylpropyl)-phosphinic acid(200698-31-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 200698-31-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

200698-31-3 Suppliers

Recommended suppliers

200698-31-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 200698-31-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,6,9 and 8 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 200698-31:
(8*2)+(7*0)+(6*0)+(5*6)+(4*9)+(3*8)+(2*3)+(1*1)=113
113 % 10 = 3
So 200698-31-3 is a valid CAS Registry Number.

200698-31-3Upstream product

200698-31-3Downstream Products

200698-33-5 2,4-di(benzyloxycarbonyl)-butyl(4-methylbenzyl)-o-benzylphosphinic acid

200698-31-3Relevant academic research and scientific papers

Prodrugs of NAALAdase inhibitors

-

, (2008/06/13)

The present invention relates to prodrugs of NAALADase inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat glutamate abnormalities and prostate diseases.

NAALADase inhibitors

-

, (2008/06/13)

The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NAALADase) enzyme

Certain dioic acid derivatives useful as NAALADase inhibitors

-

, (2008/06/13)

Methods of cancer treatment using naaladase inhibitors

-

, (2008/06/13)

The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NA

Inhibitors of NAALADase enzyme activity

-

, (2008/06/13)

Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors

-

, (2008/06/13)

The present invention relates to a method of treating a glutamate abnormality and a method of effecting a neuronal activity in an animal using a NAALADase inhibitor, and a pharmaceutical composition comprising an effective amount of a NAALADase inhibitor

PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS

-

, (2008/06/13)

The present invention relates to a pharmaceutical composition and a method for treating a compulsive disorder using a NAALADase inhibitor.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 200698-31-3